1XU.F Entheon Biomedical Corp.
- Market cap
- EUR 416K
- P/E
- 3.0x
- P/B
- 1.36x
- ROE
- 64.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to May 2026.
Is 1XU.F undervalued?
Graham number1XU.F trades 57.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Entheon Biomedical Corp. fundamental analysis
No fundamental analysis for Entheon Biomedical Corp. yet.
Entheon Biomedical Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Entheon Biomedical Corp.
Entheon Biomedical Corp. operates as a biotechnology research and development company. It develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Full company profileEntheon Biomedical Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Entheon Biomedical Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 190K | 250K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.13K | - | 250K | 0.00 | 0.00 | - |
| Operating Income | -8.21M | -3.60M | -313K | -333K | -334K | -404K |
| EBITDA | - | -3.60M | -313K | -333K | -334K | -404K |
| Net Income | -8.89M | -8.52M | -300K | -318K | -324K | 311K |
| EPS | -1.50 | -1.44 | -0.05 | -0.04 | -0.02 | 0.02 |
| Balance Sheet | ||||||
| Total Assets | 9.98M | 769K | 401K | 185K | 354K | 522K |
| Total Liabilities | 928K | 155K | 85.3K | 39.8K | 29.8K | 42.5K |
| Shareholders' Equity | 9.05M | 615K | 316K | 145K | 324K | 480K |
| Cash & Short-term Investments | 2.05M | 680K | 345K | 136K | 322K | 324K |
| Cash Flow | ||||||
| Operating Cash Flow | -5.62M | -1.95M | -360K | -356K | -315K | 4.95K |
| Capital Expenditure | 98.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -5.62M | -1.95M | -360K | -356K | -315K | 4.95K |
| Ratios | ||||||
| ROE | -98.2% | -1,386.4% | -95.0% | -218.8% | -100.0% | 64.8% |
| ROA | -89.1% | -1,107.7% | -74.8% | -171.7% | -91.6% | 59.6% |
| Net Profit Margin | - | -4,492.2% | -119.8% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Entheon Biomedical Corp. dividends
Entheon Biomedical Corp. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Mar 1, 2024.
Who owns Entheon Biomedical Corp.
- Insiders 4.82%
- Institutions 0.00%
- Public & others 95.18%
- Shares outstanding 13.9M
- Free float 13.1M
Entheon Biomedical Corp. company profile
- Company name
- Entheon Biomedical Corp.
- Ticker
- 1XU.F
- ISIN
- CA29383X2023
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- November
- Address
- 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
- Phone
- 604-562-3932
- Website
- entheonbiomedical.com
About Entheon Biomedical Corp.
Entheon Biomedical Corp. operates as a biotechnology research and development company. It develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Entheon Biomedical Corp. management
3- Mr. Timothy KoPresident, CEO, Corporate Secretary & Director · born 1986
- Mr. Soo-Whan KimInterim Chief Financial Officer
- Dr. Brian E. Jahns Pharm.D.Chief Business Officer